Zhejiang Ausun Pharmaceutical Co Ltd
603229
Company Profile
Business description
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
Contact
No.5, Donghai 4th Avenue
chemical raw materials base Linhai Park East
Zhejiang Province
Taizhou317016
CHNT: +86 57685589367
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,328
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.80 | 67.50 | 0.77% |
| CAC 40 | 8,269.96 | 70.67 | 0.86% |
| DAX 40 | 24,791.57 | 175.35 | 0.71% |
| Dow JONES (US) | 50,786.01 | 80.77 | -0.16% |
| FTSE 100 | 10,341.47 | 31.73 | -0.31% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 25,929.66 | 220.23 | 0.86% |
| Nikkei 225 | 65,416.63 | 1,392.03 | 2.17% |
| NZX 50 Index | 13,204.08 | 165.84 | 1.27% |
| S&P 500 | 7,405.73 | 21.99 | 0.30% |
| S&P/ASX 200 | 8,604.20 | 70.70 | 0.83% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |